Clinical Trials · NCT07817875

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

Phase
Phase 3
Recruitment status
Recruiting
Sponsor
Eli Lilly and Company
Enrollment
150
Start date
Sep 2026
Locations
82 sites, 10 countries
Primary endpoint
Percent Change from Baseline in Body Mass Index (BMI)
View Tirzepatide compound reference